SK3102004A3 - Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny - Google Patents
Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny Download PDFInfo
- Publication number
- SK3102004A3 SK3102004A3 SK310-2004A SK3102004A SK3102004A3 SK 3102004 A3 SK3102004 A3 SK 3102004A3 SK 3102004 A SK3102004 A SK 3102004A SK 3102004 A3 SK3102004 A3 SK 3102004A3
- Authority
- SK
- Slovakia
- Prior art keywords
- alkyl
- group
- substituted
- saturated
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 268
- 229920000642 polymer Polymers 0.000 title claims description 137
- 229920001281 polyalkylene Polymers 0.000 title 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims abstract description 142
- 238000000034 method Methods 0.000 claims abstract description 77
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 64
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 40
- 208000036142 Viral infection Diseases 0.000 claims abstract description 23
- 230000009385 viral infection Effects 0.000 claims abstract description 23
- 239000003443 antiviral agent Substances 0.000 claims abstract description 18
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 14
- 208000010710 hepatitis C virus infection Diseases 0.000 claims abstract description 13
- 208000006154 Chronic hepatitis C Diseases 0.000 claims abstract description 12
- -1 CONR ' Inorganic materials 0.000 claims description 482
- 125000000217 alkyl group Chemical group 0.000 claims description 260
- 229920006395 saturated elastomer Polymers 0.000 claims description 258
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 228
- 239000000203 mixture Substances 0.000 claims description 197
- 125000003118 aryl group Chemical group 0.000 claims description 163
- 150000001412 amines Chemical class 0.000 claims description 159
- 125000001072 heteroaryl group Chemical group 0.000 claims description 159
- 150000002148 esters Chemical class 0.000 claims description 156
- 229910052736 halogen Inorganic materials 0.000 claims description 155
- 150000002367 halogens Chemical class 0.000 claims description 155
- 239000002243 precursor Substances 0.000 claims description 147
- 150000001299 aldehydes Chemical group 0.000 claims description 142
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 134
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 126
- 125000001424 substituent group Chemical group 0.000 claims description 109
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 106
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 claims description 96
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 95
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 93
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 92
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 90
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 88
- 150000003457 sulfones Chemical class 0.000 claims description 88
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 87
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 85
- 125000002252 acyl group Chemical group 0.000 claims description 84
- 150000001409 amidines Chemical class 0.000 claims description 84
- 150000007942 carboxylates Chemical class 0.000 claims description 84
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 84
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 84
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 84
- 150000007970 thio esters Chemical class 0.000 claims description 84
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 claims description 84
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 84
- 125000003545 alkoxy group Chemical group 0.000 claims description 83
- 125000000623 heterocyclic group Chemical group 0.000 claims description 83
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 83
- 229910052739 hydrogen Inorganic materials 0.000 claims description 82
- 239000001257 hydrogen Substances 0.000 claims description 81
- 150000002466 imines Chemical class 0.000 claims description 81
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims description 81
- 125000003368 amide group Chemical group 0.000 claims description 80
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 76
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 76
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 72
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 71
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 71
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 71
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 71
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 71
- 150000001241 acetals Chemical class 0.000 claims description 71
- 125000003342 alkenyl group Chemical group 0.000 claims description 71
- 150000002118 epoxides Chemical class 0.000 claims description 71
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 70
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 70
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 69
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 69
- 229920002554 vinyl polymer Polymers 0.000 claims description 69
- 239000012948 isocyanate Substances 0.000 claims description 68
- 150000002513 isocyanates Chemical class 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 150000002540 isothiocyanates Chemical class 0.000 claims description 67
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims description 66
- CYWHLOXWVAWMFO-UHFFFAOYSA-N 3-sulfanyl-1h-pyridine-2-thione Chemical compound SC1=CC=CN=C1S CYWHLOXWVAWMFO-UHFFFAOYSA-N 0.000 claims description 66
- 125000004414 alkyl thio group Chemical group 0.000 claims description 63
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 62
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 58
- 150000003573 thiols Chemical class 0.000 claims description 58
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 54
- 125000005647 linker group Chemical group 0.000 claims description 53
- 229910052760 oxygen Inorganic materials 0.000 claims description 49
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 48
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 47
- 229910052717 sulfur Inorganic materials 0.000 claims description 47
- 229940015043 glyoxal Drugs 0.000 claims description 45
- 102000014150 Interferons Human genes 0.000 claims description 40
- 108010050904 Interferons Proteins 0.000 claims description 40
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 34
- 125000002619 bicyclic group Chemical group 0.000 claims description 32
- 230000000840 anti-viral effect Effects 0.000 claims description 31
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 29
- 229940079322 interferon Drugs 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 24
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 22
- 229960004461 interferon beta-1a Drugs 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
- 239000002096 quantum dot Substances 0.000 claims description 19
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 102000003996 Interferon-beta Human genes 0.000 claims description 15
- 108090000467 Interferon-beta Proteins 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 229960001388 interferon-beta Drugs 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 150000003384 small molecules Chemical class 0.000 claims description 15
- 229960002317 succinimide Drugs 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 230000013595 glycosylation Effects 0.000 claims description 5
- 238000006206 glycosylation reaction Methods 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 239000000693 micelle Substances 0.000 claims description 5
- 239000011859 microparticle Substances 0.000 claims description 5
- 239000002777 nucleoside Substances 0.000 claims description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims 20
- 229910000077 silane Inorganic materials 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 18
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 11
- 229960000329 ribavirin Drugs 0.000 claims 11
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 11
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims 10
- 229960004150 aciclovir Drugs 0.000 claims 10
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 10
- 229960002963 ganciclovir Drugs 0.000 claims 10
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 10
- 229960002555 zidovudine Drugs 0.000 claims 10
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 10
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 7
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 5
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims 3
- IQZPDFORWZTSKT-UHFFFAOYSA-N nitrosulphonic acid Chemical group OS(=O)(=O)[N+]([O-])=O IQZPDFORWZTSKT-UHFFFAOYSA-N 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- SBCKOCCNHTWDJZ-UHFFFAOYSA-N azanylidyne(sulfosulfanyl)methane Chemical compound OS(=O)(=O)SC#N SBCKOCCNHTWDJZ-UHFFFAOYSA-N 0.000 claims 2
- NZWGAJHCKIRNRL-UHFFFAOYSA-N azanylidyne(sulfosulfonyloxy)methane Chemical compound OS(=O)(=O)S(=O)(=O)OC#N NZWGAJHCKIRNRL-UHFFFAOYSA-N 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims 2
- FHBSGPWHCCIQPG-UHFFFAOYSA-N hydroxy-methyl-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound CS(S)(=O)=O FHBSGPWHCCIQPG-UHFFFAOYSA-N 0.000 claims 2
- NIWKXCIWWOTLKA-UHFFFAOYSA-N methylsulfonylsulfonylsulfonylmethane Chemical compound CS(=O)(=O)S(=O)(=O)S(C)(=O)=O NIWKXCIWWOTLKA-UHFFFAOYSA-N 0.000 claims 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 2
- 101100025413 Arabidopsis thaliana XI-B gene Proteins 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 229940043279 diisopropylamine Drugs 0.000 claims 1
- QDXBVEACAWKSFL-UHFFFAOYSA-N ethenethiol Chemical compound SC=C QDXBVEACAWKSFL-UHFFFAOYSA-N 0.000 claims 1
- SBVCEDLIWDSBGE-UHFFFAOYSA-N iminosilane Chemical compound [SiH2]=N SBVCEDLIWDSBGE-UHFFFAOYSA-N 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims 1
- BZWKPZBXAMTXNQ-UHFFFAOYSA-N sulfurocyanidic acid Chemical compound OS(=O)(=O)C#N BZWKPZBXAMTXNQ-UHFFFAOYSA-N 0.000 claims 1
- 150000008127 vinyl sulfides Chemical class 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 abstract description 6
- 238000001990 intravenous administration Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 12
- 229940047124 interferons Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 125000003147 glycosyl group Chemical group 0.000 description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000000562 conjugate Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 108010005714 Interferon beta-1b Proteins 0.000 description 3
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- NWBNORAVIXIZTL-UHFFFAOYSA-N nitro thiocyanate Chemical compound [O-][N+](=O)SC#N NWBNORAVIXIZTL-UHFFFAOYSA-N 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229960003161 interferon beta-1b Drugs 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 231100001019 reduced numbers of red blood cells Toxicity 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical group OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34991702P | 2002-01-18 | 2002-01-18 | |
| PCT/US2003/001559 WO2003061577A2 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycol with moiety for conjugating biologically active compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK3102004A3 true SK3102004A3 (sk) | 2005-01-03 |
Family
ID=27613339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK310-2004A SK3102004A3 (sk) | 2002-01-18 | 2003-01-17 | Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8017733B2 (sr) |
| EP (3) | EP3669887A1 (sr) |
| JP (5) | JP2005526151A (sr) |
| KR (1) | KR100964411B1 (sr) |
| CN (2) | CN101700401B (sr) |
| AU (1) | AU2003210564B2 (sr) |
| BE (1) | BE2016C040I2 (sr) |
| BG (1) | BG66525B1 (sr) |
| BR (1) | BRPI0306993B8 (sr) |
| CA (4) | CA2473526C (sr) |
| CY (2) | CY2016027I2 (sr) |
| CZ (1) | CZ2004877A3 (sr) |
| DK (2) | DK3025726T3 (sr) |
| EA (2) | EA009783B1 (sr) |
| EE (1) | EE05509B1 (sr) |
| ES (2) | ES2774801T3 (sr) |
| GE (2) | GEP20064024B (sr) |
| HK (3) | HK1072721A1 (sr) |
| HU (4) | HUE028163T2 (sr) |
| IL (1) | IL163006A (sr) |
| IS (1) | IS2989B (sr) |
| LU (1) | LU93162I2 (sr) |
| ME (2) | ME00239B (sr) |
| MX (1) | MXPA04006855A (sr) |
| NL (1) | NL300826I2 (sr) |
| NO (3) | NO339857B1 (sr) |
| NZ (1) | NZ534708A (sr) |
| PL (2) | PL213322B1 (sr) |
| PT (1) | PT3025726T (sr) |
| RS (1) | RS55578B1 (sr) |
| SI (2) | SI1476181T1 (sr) |
| SK (1) | SK3102004A3 (sr) |
| UA (1) | UA82184C2 (sr) |
| WO (1) | WO2003061577A2 (sr) |
| ZA (1) | ZA200406555B (sr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150246097A9 (en) * | 2002-01-18 | 2015-09-03 | Biogen Idec Ma Inc. | Polyalkylene Polymer Compounds and Uses Thereof |
| AU2003210564B2 (en) * | 2002-01-18 | 2008-10-23 | Biogen Ma Inc. | Polyalkylene glycol with moiety for conjugating biologically active compound |
| MXPA05002620A (es) | 2002-09-09 | 2005-05-05 | Nektar Therapeutics Al Corp | Alcanales polimericos solubles en agua. |
| US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| MXPA05006945A (es) * | 2002-12-26 | 2005-12-14 | Mountain View Pharmaceuticals | Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor. |
| DK1667708T5 (da) * | 2002-12-26 | 2012-11-12 | Mountain View Pharmaceuticals | Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro |
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| PL1635875T3 (pl) | 2003-06-26 | 2009-03-31 | Psivida Inc | System dostarczania leków poprzez żelowanie w warunkach in-situ |
| ATE536861T1 (de) | 2003-06-26 | 2011-12-15 | Control Delivery Sys Inc | Bioerodierbare arzneimittelabgabesysteme mit verzögerter freisetzung |
| US20090312344A1 (en) * | 2004-05-31 | 2009-12-17 | Mohammad Salman | Arylpiperazine derivatives as adrenergic receptor antagonists |
| ATE494012T1 (de) | 2004-12-21 | 2011-01-15 | Nektar Therapeutics | Stabilisierte polymer-thiol-reagenzien |
| WO2006130553A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
| CA2614200A1 (en) * | 2005-07-08 | 2007-01-18 | Elan Pharmaceuticals, Inc. | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
| WO2007137260A2 (en) * | 2006-05-22 | 2007-11-29 | Elan Pharmaceuticals, Inc. | Preparation of polymer conjugates of vla-4 antagonists via a mitsunobu' s reaction |
| WO2008066816A2 (en) * | 2006-11-28 | 2008-06-05 | The Board Of Trustees Of The University Of Illinois | Derivatization or ligaton of peptides |
| EP2176404A4 (en) * | 2007-07-11 | 2014-11-19 | Belrose Pharma Inc | POLYMERIC DRUG DELIVERY SYSTEMS WITH AN AROMATIC ALLYLIC ACID |
| WO2009009712A1 (en) * | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| CL2008002399A1 (es) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| RU2496514C2 (ru) * | 2008-06-05 | 2013-10-27 | Займоджинетикс, Инк. | Применение пэгилированных интерферонов типа iii для лечения гепатита с |
| MY156568A (en) * | 2008-07-31 | 2016-03-15 | Pharmaessentia Corp | Peptide-polymer conjugates |
| GB0823309D0 (en) * | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
| CN102428512A (zh) | 2009-06-02 | 2012-04-25 | 松下电器产业株式会社 | 下混装置、编码装置以及其方法 |
| UA109646C2 (uk) * | 2009-12-10 | 2015-09-25 | Терапевтичне застосування кон'югатів білка з полімером | |
| US20130225789A1 (en) * | 2012-02-29 | 2013-08-29 | Yi Sun | Polyethylene Glycol Having Hetero Multiple Functional Groups |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| KR101475630B1 (ko) * | 2013-05-31 | 2014-12-22 | 동국대학교 산학협력단 | 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물 |
| KR101671501B1 (ko) * | 2014-07-24 | 2016-11-03 | 에이비온 주식회사 | 페길화된 인터페론-베타 변이체 |
| RS61128B1 (sr) | 2014-08-19 | 2020-12-31 | Biogen Ma Inc | Postupak pegilacije |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| US11559567B2 (en) | 2014-11-06 | 2023-01-24 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
| ES2831079T3 (es) * | 2017-06-28 | 2021-06-07 | Construction Research & Technology Gmbh | Dispersante para partículas inorgánicas |
| US11472894B2 (en) | 2018-07-23 | 2022-10-18 | Carnegie Mellon University | Enzyme-assisted ATRP procedures |
| CN109232898A (zh) * | 2018-08-02 | 2019-01-18 | 张玲 | 一种具有抗凝血功能的聚酰亚胺新材料的制备方法 |
| CN111534458B (zh) * | 2020-04-13 | 2022-01-14 | 浙江工业大学 | 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用 |
| CN113716982B (zh) * | 2021-08-24 | 2022-05-06 | 重庆云瑞肥业有限公司 | 一种食品垃圾回收用发酵制肥装置 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| EP0082481B2 (en) | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| WO1985003934A1 (en) * | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
| GB8334102D0 (en) * | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
| JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| WO1993012145A1 (en) * | 1991-12-19 | 1993-06-24 | Baylor College Of Medicine | Pva or peg conjugates of peptides for epitope-specific immunosuppression |
| ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| PT730470E (pt) | 1993-11-10 | 2002-08-30 | Enzon Inc | Conjugados melhorados de interferao-polimero |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| AU697440B2 (en) * | 1994-12-07 | 1998-10-08 | Novozymes A/S | Polypeptide with reduced allergenicity |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AU730969B2 (en) * | 1995-10-19 | 2001-03-22 | University Of Washington | Discrete-length polyethylene glycols |
| US5702717A (en) * | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
| KR20000075983A (ko) | 1997-03-05 | 2000-12-26 | 엘. 데이예를 카렌. | 헤파타이티스 ｃ 바이러스 복제를 선택적으로 저해하는 물질을 확인하기 위한 새로운 스크리닝 방법 |
| US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| US7642323B2 (en) * | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US6448369B1 (en) * | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| JP4465109B2 (ja) * | 1997-12-17 | 2010-05-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ |
| US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| WO1999045964A1 (en) * | 1998-03-12 | 1999-09-16 | Shearwater Polymers, Incorporated | Poly(ethylene glycol) derivatives with proximal reactive groups |
| JP4574007B2 (ja) * | 1998-04-28 | 2010-11-04 | メルク・セローノ・ソシエテ・アノニム | ポリオール−ｉｆｎ−ベータ複体 |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| EA004789B9 (ru) * | 1998-10-16 | 2017-05-31 | Байоджен, Инк. | Полимерные конъюгаты бета-1а-интерферона и их использование |
| US6602952B1 (en) * | 1999-06-11 | 2003-08-05 | Shearwater Corporation | Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers |
| US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| WO2001015736A2 (en) | 1999-08-27 | 2001-03-08 | Maxygen Aps | Interferon-beta conjugates |
| US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
| ATE317868T1 (de) * | 1999-12-22 | 2006-03-15 | Nektar Therapeutics Al Corp | Sterisch gehinderte derivate von wasserlöslichen polymeren |
| US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| ES2367891T3 (es) * | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| US7053150B2 (en) * | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| ES2289091T3 (es) * | 2001-02-01 | 2008-02-01 | Biogen Idec Ma Inc. | Conjugados polimeros de neublastina y metodos para usar los mismos. |
| YU48703A (sh) | 2001-02-27 | 2006-05-25 | Maxygen Aps | Novi interferonu beta-slični molekuli |
| US7009033B2 (en) * | 2001-07-02 | 2006-03-07 | Polymer Source Inc. | Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture |
| JP4814488B2 (ja) * | 2001-10-18 | 2011-11-16 | ネクター セラピューティックス | 重合体共役物オピオイドアンタゴニスト |
| BR0214451A (pt) * | 2001-11-20 | 2006-05-30 | Pharmacia Corp | conjugados do hormÈnio do crescimento humano quimicamente modificado |
| US6956135B2 (en) * | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US7041855B2 (en) * | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| KR100488351B1 (ko) * | 2001-12-11 | 2005-05-11 | 선바이오(주) | 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체 |
| WO2003049699A2 (en) * | 2001-12-11 | 2003-06-19 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
| AU2003210564B2 (en) * | 2002-01-18 | 2008-10-23 | Biogen Ma Inc. | Polyalkylene glycol with moiety for conjugating biologically active compound |
| MXPA05002620A (es) | 2002-09-09 | 2005-05-05 | Nektar Therapeutics Al Corp | Alcanales polimericos solubles en agua. |
| DK1667708T5 (da) * | 2002-12-26 | 2012-11-12 | Mountain View Pharmaceuticals | Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro |
| US20110165122A1 (en) * | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
-
2003
- 2003-01-17 AU AU2003210564A patent/AU2003210564B2/en active Active
- 2003-01-17 BR BRPI0306993A patent/BRPI0306993B8/pt not_active IP Right Cessation
- 2003-01-17 ES ES15203017T patent/ES2774801T3/es not_active Expired - Lifetime
- 2003-01-17 EP EP19203313.2A patent/EP3669887A1/en not_active Withdrawn
- 2003-01-17 DK DK15203017T patent/DK3025726T3/da active
- 2003-01-17 EP EP15203017.7A patent/EP3025726B1/en not_active Expired - Lifetime
- 2003-01-17 CA CA2473526A patent/CA2473526C/en not_active Expired - Lifetime
- 2003-01-17 KR KR1020047011171A patent/KR100964411B1/ko active Protection Beyond IP Right Term
- 2003-01-17 DK DK03731987.8T patent/DK1476181T3/en active
- 2003-01-17 MX MXPA04006855A patent/MXPA04006855A/es active IP Right Grant
- 2003-01-17 HU HUE03731987A patent/HUE028163T2/en unknown
- 2003-01-17 SI SI200332472A patent/SI1476181T1/sl unknown
- 2003-01-17 GE GEAP8365A patent/GEP20064024B/en unknown
- 2003-01-17 CA CA2753899A patent/CA2753899C/en not_active Expired - Lifetime
- 2003-01-17 EA EA200400962A patent/EA009783B1/ru active Protection Beyond IP Right Term
- 2003-01-17 HU HUE15203017A patent/HUE047557T2/hu unknown
- 2003-01-17 HU HU0500457A patent/HU230473B1/hu unknown
- 2003-01-17 NZ NZ534708A patent/NZ534708A/en not_active IP Right Cessation
- 2003-01-17 CN CN2009102081892A patent/CN101700401B/zh not_active Expired - Lifetime
- 2003-01-17 WO PCT/US2003/001559 patent/WO2003061577A2/en active Application Filing
- 2003-01-17 CA CA2952488A patent/CA2952488C/en not_active Expired - Lifetime
- 2003-01-17 UA UA20040706173A patent/UA82184C2/uk unknown
- 2003-01-17 EE EEP200400105A patent/EE05509B1/xx unknown
- 2003-01-17 ES ES03731987.8T patent/ES2566797T3/es not_active Expired - Lifetime
- 2003-01-17 EP EP03731987.8A patent/EP1476181B1/en not_active Expired - Lifetime
- 2003-01-17 ME MEP-2008-356A patent/ME00239B/me unknown
- 2003-01-17 CA CA2840490A patent/CA2840490C/en not_active Expired - Lifetime
- 2003-01-17 SK SK310-2004A patent/SK3102004A3/sk not_active Application Discontinuation
- 2003-01-17 PL PL372728A patent/PL213322B1/pl unknown
- 2003-01-17 SI SI200332604T patent/SI3025726T1/sl unknown
- 2003-01-17 PL PL397261A patent/PL397261A1/pl unknown
- 2003-01-17 RS YU63504A patent/RS55578B1/sr unknown
- 2003-01-17 CN CNA038057972A patent/CN1630530A/zh active Pending
- 2003-01-17 EA EA200701386A patent/EA011829B1/ru not_active IP Right Cessation
- 2003-01-17 PT PT152030177T patent/PT3025726T/pt unknown
- 2003-01-17 CZ CZ2004877A patent/CZ2004877A3/cs unknown
- 2003-01-17 ME MEP-356/08A patent/MEP35608A/xx unknown
- 2003-01-17 JP JP2003561523A patent/JP2005526151A/ja active Pending
- 2003-01-17 GE GEAP20038365A patent/GEP20074024B/en unknown
-
2004
- 2004-07-14 IL IL163006A patent/IL163006A/en active Protection Beyond IP Right Term
- 2004-07-15 IS IS7353A patent/IS2989B/is unknown
- 2004-07-16 US US10/892,830 patent/US8017733B2/en active Active
- 2004-08-10 BG BG108839A patent/BG66525B1/bg unknown
- 2004-08-17 ZA ZA2004/06555A patent/ZA200406555B/en unknown
- 2004-08-17 NO NO20043422A patent/NO339857B1/no not_active IP Right Cessation
-
2005
- 2005-05-09 HK HK05103877.7A patent/HK1072721A1/zh not_active IP Right Cessation
-
2009
- 2009-04-30 JP JP2009110274A patent/JP5275125B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-01 HK HK10110235.2A patent/HK1143553A1/xx not_active IP Right Cessation
-
2011
- 2011-09-12 US US13/230,080 patent/US8524660B2/en not_active Expired - Lifetime
-
2012
- 2012-07-05 JP JP2012151745A patent/JP2012255156A/ja active Pending
-
2013
- 2013-01-21 JP JP2013008426A patent/JP2013136756A/ja not_active Abandoned
-
2015
- 2015-07-02 JP JP2015133310A patent/JP6030717B2/ja not_active Expired - Lifetime
- 2015-08-26 NO NO20151082A patent/NO344612B1/no not_active IP Right Cessation
-
2016
- 2016-08-03 LU LU93162C patent/LU93162I2/fr unknown
- 2016-08-04 BE BE2016C040C patent/BE2016C040I2/fr unknown
- 2016-08-05 CY CY2016027C patent/CY2016027I2/el unknown
- 2016-08-11 NL NL300826C patent/NL300826I2/nl unknown
- 2016-08-18 HU HUS1600035C patent/HUS1600035I1/hu unknown
- 2016-10-28 HK HK16112449.4A patent/HK1224185A1/zh not_active IP Right Cessation
-
2017
- 2017-04-10 NO NO2017013C patent/NO2017013I2/no unknown
-
2020
- 2020-02-06 CY CY20201100115T patent/CY1122841T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK3102004A3 (sk) | Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny | |
| JP2005526151A5 (sr) | ||
| AU2003210564A1 (en) | Polyalkylene glycol with moiety for conjugating biologically active compound | |
| US20170049904A1 (en) | Polyalkylene polymer compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC4A | Change of owner's name |
Owner name: BIOGEN MA INC., CAMBRIDGE, MA, US Effective date: 20160302 |
|
| FC9A | Refused patent application |